Skip to main content

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/02/insoma-stefan-profile-OTC-DCP-2024-featured-image-FINAL.jpg

How Stefan Roberts and inSoma Bio are upgrading fat grafting with Duke technology and support

Learn how the Duke community is helping BME Ph.D. graduate Stefan Roberts and his start-up inSoma Bio commercialize technology he developed in the lab of Professor Ashutosh Chilkoti.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/02/basking-biosciences-logo.png

Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke

Basking Biosciences, a start-up out of the lab of Professor Bruce Sullenger (Surgery, SOM), is developing a next-gen treatment for stroke.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/01/otc-timeline-announcement-featured-image.jpg

Duke is Inventive: A Century of Innovation at Duke University

A new Centennial physical and digital exhibit from OTC collects innovations, inventors, and companies spinning out of Duke University.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2023/12/Humacyte_Logo.jpg

Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma

Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2023/12/TEN63_RGB_v2_nobackground_Logo.jpg

Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim

Ten63 is a Duke University start-up and DCP portfolio company out of the lab of Professor Bruce Donald (Computer Science, Trinity).

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/09/Tune-TherapeuticsTune-Therapeutics.jpeg

Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B

Tune Therapeutics is a Duke start-up and DCP portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2023/12/invented-at-duke.2023.0253.jpg

Invented at Duke 2023 – Engineering highlights

The Pratt School of Engineering was a big participant in the 5th Annual Invented at Duke, with multiple inventors and resources. Watch the video here.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2023/11/1-header-128.jpg

Invented at Duke 2023 showcases a bustling innovation ecosystem

Featuring inventor booths, innovation resources, and strong support in speeches from leaders, Invented at Duke 2023 caps a big year for OTC.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2023/11/stem_cells_type_1_diabetes.webp

Can nanosensor technology and stem cell transplants revolutionise type 1 diabetes treatment? – Diabetes Voice

Minutia is a next generation cell therapy start-up co-founded by cell sensing luminary Professor Tuan Vo-Dinh (BME, Pratt).

Read More

1 5 6 7 8 9 32